How big is Catalyst Biosciences, Inc.?

As of Jun 18, Catalyst Biosciences, Inc. has a market capitalization of 694.30 million, with net sales of 100.65 million and a net profit of 11.70 million reported over the latest four quarters.

Market Cap: As of Jun 18, Catalyst Biosciences, Inc. has a market capitalization of 694.30 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Catalyst Biosciences, Inc. reported net sales of 100.65 million and a net profit of 11.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 63.32 million and total assets of 125.41 million.

What does Catalyst Biosciences, Inc. do?

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions. As of March 2025, it reported net sales of $22 million and a net profit of $4 million, with a market cap of $694.30 million.

Overview:<BR>Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for serious medical conditions in the pharmaceuticals and biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Net Sales: 22 Million (Quarterly Results - Mar 2025)<BR>- Net Profit: 4 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 694.30 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 94.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.43<BR>- Return on Equity: 11.32%<BR>- Price to Book: 10.19<BR><BR>Contact Details:<BR>- Address: 611 Gateway Blvd Ste 710, SOUTH SAN FRANCISCO CA: 94080-7029<BR>- Tel: 1 650 8710761<BR>- Fax: 1 302 6365454<BR>- Website: http://www.catalystbiosciences.com/

Should I buy, sell or hold Catalyst Biosciences, Inc.?

Who are in the management team of Catalyst Biosciences, Inc.?

As of March 2022, the management team of Catalyst Biosciences, Inc. includes Mr. Augustine Lawlor (Independent Chairman), Dr. Nassim Usman (CEO), and several independent directors: Dr. Errol De Souza, Ms. Andrea Hunt, Dr. Geoffrey Ling, Ms. Sharon Tetlow, and Mr. Edward Williams. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Catalyst Biosciences, Inc. includes the following individuals:<BR><BR>- Mr. Augustine Lawlor, Independent Chairman of the Board<BR>- Dr. Nassim Usman, President, Chief Executive Officer, and Director<BR>- Dr. Errol De Souza, Independent Director<BR>- Ms. Andrea Hunt, Independent Director<BR>- Dr. Geoffrey Ling, Independent Director<BR>- Ms. Sharon Tetlow, Independent Director<BR>- Mr. Edward Williams, Independent Director<BR><BR>This team comprises a mix of leadership roles and independent directors, contributing to the governance and strategic direction of the company.

Is Catalyst Biosciences, Inc. overvalued or undervalued?

As of May 9, 2025, Catalyst Biosciences, Inc. is considered overvalued due to its high P/E ratio of 94 and significant underperformance with a year-to-date return of -36.45%, compared to the S&P 500's 12.22%.

As of 9 May 2025, the valuation grade for Catalyst Biosciences, Inc. has moved from fair to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its high P/E ratio of 94, a Price to Book Value of 10.60, and an EV to EBITDA ratio of 57.11, which are significantly higher than its peers. For instance, Equillium, Inc. has a P/E ratio of -5.54, and OncoCyte Corp. shows a P/E of -2.92, highlighting the relative overvaluation of Catalyst.<BR><BR>The company's stock has underperformed compared to the S&P 500, with a year-to-date return of -36.45% versus the index's 12.22%, and a staggering 5-year return of -89.36% compared to the S&P's 96.61%. This significant underperformance reinforces the conclusion that Catalyst Biosciences, Inc. is currently overvalued.

Is Catalyst Biosciences, Inc. technically bullish or bearish?

As of August 12, 2025, Catalyst Biosciences, Inc. shows a mildly bearish trend influenced by daily moving averages, while underperforming the S&P 500 with a year-to-date decline of 36.45%.

As of 12 August 2025, the technical trend for Catalyst Biosciences, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD and KST show mild bullishness. However, Bollinger Bands and OBV suggest bearishness on the monthly timeframe. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date decline of 36.45% versus the S&P 500's gain of 12.22%.